placebo-controlled trial is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4 melanocortin receptor | Other melanocortin subtypes are also activated |
| Typical route in approved use | Subcutaneous injection | Single-use format in the marketed product |
| Elimination half-life | Roughly two to three hours | Short exposure supports as-needed use |
| Common adverse events | Nausea, flushing, headache | Generally transient but can be dose limiting |
| Main studied group | Premenopausal women with low desire | Controlled data outside this group are limited |
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Removing the algae underwater without disrupting native flora is accomplished by humans diving underwater and manually removing the reproductive parts of the wakame to reduce its spread. Proper and regular cleaning of underwater apparatus reduces the potential vectors for wakame spores, reducing the spread of the seaweed.
== Bibliography == The Ice Opinion: Who Gives a Fuck? (1994), with Heidi Siegmund Ice: A Memoir of Gangster Life and Redemption – from South Central to Hollywood (2011), with Douglas Century Split Decision: Life Stories (2022), with Spike and Douglas Century Death for Hire: The Origin of Tehk City (2023), with Arabian Prince Kings of Vice novel series
Australia's first federal labour rights followed the Constitution of Australia in 1901, yet the law had long regulated work in colonies, often violently suppressing labour freedom. The land of Australia was forcibly settled by British Empire migrants, who anchored in Botany Bay and then declared they held possession of the eastern continent in 1780. After losing territory to the United States in the American War of Independence, Britain established a penal colony of 1400 settlers and convicts in Sydney in 1788. Before colonisation, there were around 1.2 million Indigenous Australians, but contact with European settlers killed up to 80% of people through smallpox and other diseases. In the Australian frontier wars over the next century, around 115,000 Indigenous people were massacred or killed, particularly in Queensland. Indigenous Australian labour was typically organised on hunter-gathering lines, and was cooperative within and between tribes, and through trade among national groups. By contrast, British labour was primarily forced, with a constant supply of prisoners from the British Isles whose crimes were often related to poverty or trying to seek better wages. For example, in R v Lovelass a group of five farm workers in Tolpuddle, Dorset had organised a trade union, because their wages were cut from nine shillings to a starvation wage of six shillings a week. They were convicted under the Unlawful Oaths Act 1797 and Unlawful Societies Act 1799 and sentenced to transportation to Sydney.
Sources: en.wikipedia.org
Reconstruction of paleoenvironments of the sources. Because of the high-sensitivity of D content of terrestrial water to hydrological cycles, organic δD can reflect the environment of source formation. To the first order, DHRs of coals and n-alkanes from oils have been shown to correlate with paleolatitude. Source correlation. Marine and lacustrine environments are characterized by distinctly different δD values. Many studies have tried to relate measured δD with source types. For methane, D concentration and clumped isotopes is particularly diagnostic of sources. Possible maturity indicators. For example, isoprenoids synthesized by plants are strongly depleted in D (See "Observed variations in isotopic abundance" section), typically ~100‰ to n-alkyl lipids. This gap tends to decrease as rock matures because of the higher D/H exchange rates of isoprenoids. The correlation of δD difference between pristane, phytane and n-alkanes and other maturity indicators has been established across a wide maturity range. Another possible maturity indicator based on the "isotope slope" of δD vs. n-alkane chain length was proposed by Tang et al. Quantitative apportionment. Since alkanes are main components of oil and gas, the isotopic data of n-alkanes have been used to study their migration and mixing. The advantage of hydrogen isotopes over carbon is higher resolution because of larger fractionation. Studying the clumped isotopes of methane provides a new dimension of mixing-constraints. The mixing line in the clumped isotope notation space is a curve rather than a straight line.
Chronometric dating is a process of archaeological and geological age determination. Often confused with Absolute dating, Chronometric dating measures time through consistent natural processes (such as the degradation of the C14 atom) and provides a date range, not an absolute date, to the dated event.
== Honors and awards == 1981–1982: Fogarty International Scholar 1981: Honorary Member of the American Society of Biological Chemistry 1984: Rothschild Prize in Chemistry 1987: Wolf Prize in Medicine, jointly with Pedro Cuatrecasas, "for the invention and development of affinity chromatography and its applications to biomedical sciences." 1987: Pierce Prize for Biorecognition Technology 1988: Elected Member of the Israel Academy of Sciences and Humanities 1989: Doctor of Science, honoris causa, University of Waterloo, Canada 1989: Barnett Lecturer, Northeastern University, Boston 1990: Israel Prize, in life sciences 1990: Sarstedt Prize (Numbrecht, Germany) 1993: Foreign Associate Member, Institute of Medicine, National Academy of Science, USA 1995: Doctor of Science, honoris causa, Bar Ilan University, Israel 1996: International Distinguished Clinical Chemist Award, International Federation of Clinical Chemistry (IFCC) 2000: Doctor of Science, honoris causa, University Jyvaskyla, Finland 2000: Honorary Doctorate, Ben-Gurion University of the Negev 2002: Honorary Citizen, City of Rehovot, Israel 2004: Wilhelm Exner Medal. 2004: Christian B. Anfinsen Award of The Protein Society 2004: Wilhelm-Exner Medal, OGV, President of Austria 2005: Emet Prize, presented by the Prime Minister of Israel
=== Reproduction === In animals, relaxin widens the pubic bone and facilitates labor; it also softens the cervix (cervical ripening), and softens the pubic symphysis in rat and guinea pig models. Thus, for a long time, relaxin was looked at as a pregnancy hormone. However, its significance may reach much further. Relaxin may affect collagen metabolism, inhibiting collagen synthesis and enhancing its breakdown by increasing matrix metalloproteinases. It also enhances angiogenesis and is a potent renal vasodilator. In horses (Equus caballus), relaxin is also an important hormone involved in pregnancy; however, before pregnancy occurs, relaxin is expressed by ovarian structures during the oestrous cycle. Prior to ovulation, relaxin will be produced by ovarian stromal cells, which will promote secretion of gelatinases and tissue inhibitors of metalloproteinases. These enzymes will then aid the process of ovulation, which will lead to the release of a developed follicle into the fallopian tube. Furthermore, granular and theca cells in the follicles will express relaxin in increasing levels depending on their size. During early pregnancy, the preimplantation conceptus will express relaxin, which will promote angiogenesis in the endometrium by up-regulating VEGF. This will allow the endometrium to prepare for implantation. In horses alone, the embryo in the uterus will express relaxin mRNA at least 8 days after ovulation. Then as the conceptus develops expression will increase, which is likely to promote embryo development.
Sources: en.wikipedia.org
=== Light microscopy === Light microscopy can be used to magnify the structure of dinosaur eggshell for scientific research. To do so an eggshell fragment must be embedded in epoxy resin and sliced into a thin section with a thin-bladed rock saw. This basic method was invented by French paleontologist Paul Gervais and has remained almost unchanged ever since. Horizontally cut thin sections are called tangential thin sections while vertically cut thin sections are called radial sections. Regardless of direction, the sample must be abraded by fine-grit sand or emery paper until it is translucent. Then the structure of the shell's calcite crystals or pores can be examined under a petrographic microscope. The calcite crystal structure of dinosaur eggshell can be classified by their effect on polarized light. Calcite is capable of acting as a polarizing light filter. When a microscopic thin section sample is rotated relative to polarized light it can eventually block all the light and seem opaque. This phenomenon is called extinction. Different varieties of dinosaur eggs with their different calcite crystal structures have different light extinction properties that can be used to identify and distinguish even eggs that seem very similar on the surface. To reconstruct the three-dimensional structures of the shell's pore channels scientists require a series of multiple radial sections.
The Vietnam War descended into a quagmire for the United States, leading to a decline in international prestige and economic stability, derailing arms agreements, and provoking domestic unrest. America's withdrawal from the war led it to embrace a policy of détente with both China and the Soviet Union.
=== Tempe kering === Also known as kering tempe (lit: 'dry tempeh'), or sambal goreng tempe if mixed with plenty of hot and spicy sambal chili pepper sauce. It is a crispy, sweet and spicy, fried tempeh. The raw tempeh is cut into small sticks and thoroughly deep-fried until no longer moist, and then mixed with palm sugar, chili pepper or other spices, or with sweet soy sauce. Often it is mixed with separately fried peanuts and anchovies (ikan teri). This dry tempeh will keep for up to a month if cooked and stored properly.
Sources: en.wikipedia.org
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.
It means the product is taken shortly before anticipated activity instead of every day. This pattern reduces total exposure and shapes how safety monitoring is planned. It also means effects are expected to be temporary rather than cumulative.
Desire is assessed through validated self-report questionnaires, sometimes paired with event counts and a distress scale. These instruments capture subjective experience, so results depend on how participants interpret the questions. No laboratory marker currently substitutes for such reporting.
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.